Point72 Asset Management L.P. Makes New Investment in Autolus Therapeutics plc (NASDAQ:AUTL)

Point72 Asset Management L.P. bought a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) in the fourth quarter, HoldingsChannel reports. The firm bought 247,089 shares of the company’s stock, valued at approximately $581,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AUTL. Jane Street Group LLC acquired a new position in Autolus Therapeutics during the fourth quarter worth about $26,000. Barclays PLC raised its position in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after acquiring an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC acquired a new position in Autolus Therapeutics during the fourth quarter worth about $35,000. Arkadios Wealth Advisors acquired a new position in Autolus Therapeutics during the fourth quarter worth about $47,000. Finally, Daiwa Securities Group Inc. raised its position in Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after acquiring an additional 8,479 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.53 on Friday. The firm has a 50 day simple moving average of $1.43 and a 200-day simple moving average of $2.09. The firm has a market cap of $407.20 million, a PE ratio of -1.26 and a beta of 1.77. Autolus Therapeutics plc has a 1-year low of $1.11 and a 1-year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. As a group, sell-side analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on AUTL. Wells Fargo & Company cut their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 21st. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Finally, Truist Financial cut their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $9.32.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.